Vertex Pharma (VRTX) Tops Q3 EPS by 23c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $517.49 --0%
EPS Growth %: -0.8%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
PHAR, EEFT, INIO, More
EPS Growth %: -0.8%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
PHAR, EEFT, INIO, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $4.80, $0.23 better than the analyst estimate of $4.57. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $3.05 billion.
GUIDANCE:
Vertex Pharma sees FY2025 revenue of $11.9-12 billion, versus the consensus of $12.002 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Independent Bank (IBCP) Misses Q3 EPS by 11c
- Wells Fargo says positioning rotation over, time to pick stocks
- Citi upgrades Ferguson Enterprises to Buy with $288 target
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
